VTGN News and Press, VistaGen Therapeutics Inc. From 07/22/22

Clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN ) announced on Friday that the company’s PALISADE-1 Phase 3 clinical trial for anxiety therapy PH94B did not meet the primary endpoint. The multi-center, placebo-controlled study was designed to evaluate PH...

PH94B for Acute Treatment of Social Anxiety Disorder Did Not Meet Primary Endpoint PH94B Showed a Favorable Safety and Tolerability Profile among Study Participants that was Consistent with Prior Clinical Trial Results VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (Vist...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, is slated to attend the upcoming ...

Leaders will explore public and private sector solutions to social challenges VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, a...

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that its CEO Sha...

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that Chief Ex...

VistaGen Therapeutics (NASDAQ:VTGN) stock down 7.6% after the company posted lower-than-expected full year result. The company's revenue rose 1.7% Y/Y to $1.11M, but missed estimates by $0.21M. The company's FY GAAP EPS of -$0.25 missed estimates by $0.03 as costs increased. Re...

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today provided a corporate updat...

VistaGen Therapeutics, Inc. (VTGN) Q4 2022 Earnings Conference Call June 23, 2022 05:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chie...

VistaGen Therapeutics press release (NASDAQ:VTGN): FY GAAP EPS of -$0.25 misses by $0.03. Revenue of $1.11M (+1.8% Y/Y) misses by $0.21M. At March 31, 2022, the Company had cash and cash equivalents of approximately $68.1 million. Completed last patient out milestone for PALISADE-1 Phase 3 cl...